Fig. 3

Knockdown of ALCAT1 or inhibition of cardiolipin oxidation ameliorated kidney injury. A Illustration of the Animal Model Construction Pathway. B Immunohistochemical staining and semiquantitative analysis of ALCAT1 in glomeruli from each group (n = 6, **p<0.01, ns p>0.05, scale bars: 40 μm). C Immunofluorescence double staining and semiquantitative analysis of ALCAT1 and synaptopodin in glomeruli in each group (n = 6, *p<0.05, ns p>0.05, scale bars: 40 μm). D ALCAT1 protein levels in each group evaluated by Western blot (n = 6, *p<0.05, ****p<0.0001, ns p>0.05). E-G Body weight, blood sugar and urinary albumin creatinine ratio (UACR) from each group (n = 6, *p<0.05, #p<0.0001). H Results of 24-hour urine protein quantification (n = 6, ***p<0.001, ****p<0.0001). I Pathological damage detection by HE and PAS staining of kidney sections and quantification of the extent of mesangial expansion (n = 6, *p<0.05, ***p<0.001, scale bars: 30 μm). J Ultrastructure of capillary loops according to transmission electron microscopy in each group (n = 6, scale bars: 6 μm)